Literature DB >> 29122897

Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia.

Sanah Sajawal1, Sarah L Mackie2, Peter Hillmen3, Dennis McGonagle4.   

Abstract

We report a patient with chronic lymphocytic leukaemia (CLL) who was treated with idelalisib, a PI3Kδ inhibitor with rituximab. After 20 weeks of treatment, the patient developed classical signs and symptoms of polymyalgia rheumatica (PMR) in association with an elevated C reactive protein of 74 mg/L. After 2 weeks of prednisolone 15 mg daily symptoms had resolved and acute phase markers normalised. To our knowledge, this is the first report of PMR developing as a complication of PI3Kδ inhibitor treatment of CLL. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  haematology (drugs And Medicines); musculoskeletal syndromes

Mesh：

Substances：

Year:  2017        PMID： 29122897      PMCID： PMC5695391          DOI： 10.1136/bcr-2017-221065

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  30 in total

Review 1.  Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis.

Authors:  A Bhatia; P J Ell; J C W Edwards
Journal:  Ann Rheum Dis       Date:  2005-07       Impact factor: 19.103

Review 2.  Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature.

Authors:  Pierluigi Macchioni; Luigi Boiardi; Mariagrazia Catanoso; Lia Pulsatelli; Nicolò Pipitone; Riccardo Meliconi; Carlo Salvarani
Journal:  Semin Arthritis Rheum       Date:  2013-02-20       Impact factor: 5.532

3.  An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.

Authors:  Chie Miyabe; Yoshishige Miyabe; Klemen Strle; Nancy D Kim; John H Stone; Andrew D Luster; Sebastian Unizony
Journal:  Ann Rheum Dis       Date:  2016-12-07       Impact factor: 19.103

4.  Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

Authors:  Benjamin L Lampson; Siddha N Kasar; Tiago R Matos; Elizabeth A Morgan; Laura Rassenti; Matthew S Davids; David C Fisher; Arnold S Freedman; Caron A Jacobson; Philippe Armand; Jeremy S Abramson; Jon E Arnason; Thomas J Kipps; Joshua Fein; Stacey Fernandes; John Hanna; Jerome Ritz; Haesook T Kim; Jennifer R Brown
Journal:  Blood       Date:  2016-05-31       Impact factor: 22.113

5.  Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4.

Authors:  Barbara L Goldstein; Lydia Gedmintas; Derrick J Todd
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

6.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

7.  Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.

Authors:  Rasha Abu-Eid; Raed N Samara; Laurent Ozbun; Maher Y Abdalla; Jay A Berzofsky; Kevin M Friedman; Mikayel Mkrtichyan; Samir N Khleif
Journal:  Cancer Immunol Res       Date:  2014-07-30       Impact factor: 11.151

8.  Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: a coincidental coexistence or a causal relationship?

Authors:  G Espinosa; J Font; F J Muñoz-Rodríguez; R Cervera; M Ingelmo
Journal:  Clin Rheumatol       Date:  2002-08       Impact factor: 2.980

Review 9.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

Authors:  J M Michot; C Bigenwald; S Champiat; M Collins; F Carbonnel; S Postel-Vinay; A Berdelou; A Varga; R Bahleda; A Hollebecque; C Massard; A Fuerea; V Ribrag; A Gazzah; J P Armand; N Amellal; E Angevin; N Noel; C Boutros; C Mateus; C Robert; J C Soria; A Marabelle; O Lambotte
Journal:  Eur J Cancer       Date:  2016-01-05       Impact factor: 9.162

10.  Polymyalgia rheumatica in a renal transplant patient.

Authors:  Satyaki Banerjee; Godela Brosnahan
Journal:  J Ark Med Soc       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.